
Treatment plan review committee
The Korean government committee that reviews each advanced regenerative medicine research plan and treatment plan before a designated institution may use it.
The committee belongs jointly to the Ministry of Health and Welfare and the Ministry of Food and Drug Safety. A designated institution must write a treatment plan and have it reviewed before offering advanced regenerative treatment. The law asks the committee to consider safety, effectiveness, medical justification and need, results of earlier research, cost levels in Korea and abroad, and safety measures for patients.
An approved treatment plan can be offered for up to five years from the approval notice, after which it must be reviewed again. Lists of approved plans are posted on k-arm.go.kr.
Practical check: ask the clinic for the name of the approved plan that covers you, and check that your condition is the one the plan was approved for.
Related terms
- Designated advanced regenerative medicine institution
- A Korean hospital or clinic designated by the Ministry of Health and Welfare to carry out advanced regenerative medicine.
- Advanced Regenerative Bio Act
- Korea’s main law on regenerative treatments that use human cells, and on medicines made from cells, genes or engineered tissue.
- Clinical research
- Research on people that tests an advanced regenerative therapy under a reviewed plan, separate from routine treatment.
- Ministry of Food and Drug Safety (MFDS)
- Korea’s regulator for food and medicines, including advanced biopharmaceuticals such as cell therapy products.
Read next
Not sure where to start?
Send your question and any X-ray or MRI report you have. COMEDI, the registered coordinator that runs this guide, replies in writing and can ask a clinic for its written answer and an itemised quote.